

YOUNG UROLOGIC ONCOLOGISTS FORUM

WEDNESDAY, DECEMBER 3, 2008

Location: Cabinet/Judiciary Suite; Hyatt Regency Bethesda

6:00 p.m. – 9:30 p.m.

Young Urologic Oncologist (Y.U.O.) Dinner Program

6:30 p.m. – 7:00 p.m.

Update on SUO Long-Range Planning Activities

Martin E. Gleave, MD
The Prostate Centre at VGH

7:00 p.m. – 7:30 p.m.

Young Urologic Oncologists (Y.U.O.) Investigator Award Presentation

Jodi Kathleen Maranchie, MD
University of Pittsburgh

7:30 p.m. – 8:45 p.m.

Young Urologic Oncologists (Y.U.O.) Podium Presentations

Moderator: Jonathan Coleman, MD
Memorial Sloan-Kettering Cancer Center

7:30 p.m. # 1

MULTI-INSTITUTIONAL VALIDATION OF THE PREDICTIVE VALUE OF KI-67 LABELING INDEX IN PATIENTS WITH URINARY BLADDER CANCER

Vitaly Margulis, MD, Yair Lotan, MD, Pierre Karakiewicz, MD, Yves Fradet, MD, Raheela Ashfaq, MD, Umberto Capitanio, MD, Francesco Montorsi, MD, Patrick Bastian, MD, Matthew Nielsen, MD, Stefan Muller, MD, Jerome Rigaud, MD, Seth Lerner, MD, George Netto, MD, Arthur Sagalowsky, MD and Shahrokh Shariat, MD (Presented By: Vitaly Margulis)

7:45 p.m. # 2

CYP17 POLYMORPHISMS AND PROSTATE CANCER RISK AND MORTALITY

Jonathan L. Wright^{1,2}, Daniel W. Lin^{1,2}, Erika M. Kwon⁴, Suzanne Kolb², Ziding Feng³, Joseph Koopmeiners³, Elaine A. Ostrander⁴, Janet L. Stanford^{2,5} (Presented By: Jonathan Wright)
¹Department of Urology, University of Washington School of Medicine, Seattle, WA; ²Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Department of Biostatistics, University of Washington School of Public Health, Seattle, WA; ⁴Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, MD; ⁵Department of Epidemiology, University of Washington School of Public Health, Seattle, WA

8:00 p.m. # 3

IMAGE GUIDED PHOTOTHERMAL TARGETED THERAPY FOR LOW RISK LOCALIZED PROSTATE CANCER

Uri Lindner, MD², Massom A. Haider, MD, FRCPC¹, Robert A. Weersink, PhD¹, Sean R.H. Davidson, MASc¹, Mark R. Gertner, PhD¹, Mostafa Atri, MD, FRCPC³ and John Trachtenberg, MD, FRCSC¹ (Presented By: Uri Lindner)
¹Princess Margaret Hospital, University of Toronto; ²Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada; ³Sunnybrook Health Science Centre, University of Toronto, Toronto, ON, Canada

8:45 p.m. – 9:30 p.m.

Y.U.O. Business Meeting

Continues on next page

39

YOUNG UROLOGIC ONCOLOGISTS FORUM

Continued from previous page

FRIDAY, DECEMBER 5, 2008

Location: NIH, Natcher Center

8:00 a.m. – 8:30 a.m.

Young Urologic Oncologists (YUO)

Moderator: Jonathan Coleman, MD

Memorial Sloan-Kettering Cancer Center

Selected YUO Podium Abstract Presentations

8:00 a.m. # 4

UPREGULATION OF TRAG3 (TAXOL RESISTANCE ASSOCIATED GENE 3) IS ASSOCIATED WITH ADVANCED BLADDER CANCER (BCA)

Jose Karam, MD⁴, Sandra Huang⁴, Jinhai Fan⁴, Jennifer Stanfield⁴, Roger Schultz², Rey-Chen Pong⁴, Xiankai Sun³, Xian-Jin Xie¹, Arthur Sagalowsky⁴ and Jer-Tsong Hsieh⁴ (Presented By: Jose Karam)

¹Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX; ²Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX; ³Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX; ⁴Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX

8:10 a.m. # 5

COMPARISON OF PRIMARY AND METASTATIC TO LYMPH NODE CELL LINES FROM THE SAME PATIENTS

Kiranpreet Khurana, Nick W. Liu, BS, Ariel Reinish, Youfeng Yang, PhD, Vladimir Valera, PhD, Cathy Vocke, PhD, Peter A. Pinto, MD, W. Marston Linehan, MD and Gennady Bratslavsky, MD (Presented By: Kiranpreet Khurana)
Bethesda, MD

8:20 a.m. # 6

CLINICAL OUTCOMES IN CLINICAL STAGE III NSGCT PATIENTS WHO ACHIEVE A COMPLETE RADIOGRAPHIC RESPONSE TO CHEMOTHERAPY AT THE SITE OF EXTRA-RETROPERITONEAL DISEASE

Timothy A. Masterson, MD, Brett S. Carver, MD, Robert J. Motzer, MD, George J. Bosl, MD and Joel Sheinfeld, MD (Presented By: Timothy A. Masterson)
MSKCC, New York, NY